A5055720530- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Radiotherapy Techniques
- Cancer therapeutics and mechanisms
- Economic and Financial Impacts of Cancer
- Histone Deacetylase Inhibitors Research
- Cancer survivorship and care
- Gastric Cancer Management and Outcomes
- Brain Metastases and Treatment
- Angiogenesis and VEGF in Cancer
- Genomics, phytochemicals, and oxidative stress
- Childhood Cancer Survivors' Quality of Life
- Genetics and Neurodevelopmental Disorders
- Palliative Care and End-of-Life Issues
- Medical Imaging and Pathology Studies
- Cancer, Hypoxia, and Metabolism
Stanford University
2015-2025
VA Palo Alto Health Care System
2015-2025
Amrita Vishwa Vidyapeetham
2024
Stanford Medicine
2024
Palo Alto University
2010-2024
Cancer Prevention Institute of California
2021-2023
Stanford Cancer Institute
2014-2023
Palo Alto Institute
2021
Stratford University
2020
Cancer Institute (WIA)
2018
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple types, but whether further can improve outcomes patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 consolidation immune checkpoint inhibition (CICI). Patients undetectable after CRT had excellent or not they received CICI. Among such...
Tumor genotyping is not routinely performed in localized non-small cell lung cancer (NSCLC) due to lack of associations mutations with outcome. Here, we analyze 232 consecutive patients NSCLC and demonstrate that KEAP1 NFE2L2 are predictive high rates local recurrence (LR) after radiotherapy but surgery. Half LRs occurred tumors KEAP1/NFE2L2 mutations, indicating they major molecular drivers clinical radioresistance. Next, functionally evaluate our cohort only pathogenic associated...
Abstract Purpose: Activation of NFE2L2 has been linked to chemoresistance in cell line models. Recently, somatic mutations that activate NFE2L2, including KEAP1, or CUL3, have found be associated with poor outcomes patients non–small lung cancer (NSCLC). However, the impact these on remains incompletely explored. Experimental Design: We investigated effect Keap1 deletion lines from Trp53-based mouse models squamous carcinoma (LSCC) and adenocarcinoma (LUAD). Separately, we identified 51...
Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), deubiquitinating enzyme, is elevated in tissues plasma from patients with carcinomas. Loss of UCHL1 decreases tumor growth inhibits metastasis these malignancies. maintains differentiation promotes progression by regulating nucleoporin, POM121, p53. binds, deubiquitinates,...
To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer. An Expert Panel medical oncology, thoracic surgery, radiation pulmonary, community research methodology, and advocacy experts were convened conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials published from 1990 through 2022. Outcomes interest response rates, overall survival, disease-free survival or...
Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small up 10 cm3 in volume be well controlled with a biologically effective dose less than 100 Gy.
Patients with metastatic cancer benefit from advance care planning (ACP) conversations. We aimed to improve ACP using a computer model select high-risk patients, shorter predicted survival, for conversations providers and lay coaches. Outcomes included documentation frequency end-of-life quality measures.In this study of improvement initiative, in four medical oncology clinics received Serious Illness Care Program training. Two (thoracic/genitourinary) participated an intervention, two...
The Veterans Health Administration (VHA) has pioneered teleoncology to address access challenges faced by requiring cancer care. This ASCO Educational Book highlights the development of programs within VHA: local VA Pittsburgh Healthcare System (VAPHS) Virtual Cancer Care Center, National TeleOncology Program (NTO), and regional Clinical Resource Hub (CRH) Oncology Program. These initiatives provide oncology care using a hub-and-spoke model, which centralizes expertise at hub sites reaches...
Abstract The complementarity and clinical utility of combining liquid biopsies radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT develop validate a novel dynamic risk model that accurately predicts ultimate progression-free...